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Background: Patients in intensive care units receive many drugs simultaneously but through limited venous
accesses. Several intravenous therapies have to be administered through the same catheter, thus increasing the risk
of physicochemical incompatibility. The purpose of this work was to assess and to quantify the impact of physical
incompatibility on the mass flow rates of drugs infused simultaneously to the patient, through an in vitro study.
Methods: Furosemide-midazolam incompatibility was used to assess the impact of physical incompatibility on drug
mass flow rates. Furosemide, midazolam, and saline were simultaneously infused. A filter was added at the end of
the infusion line to retain visible particles. Two infusion conditions were tested with and without visible particles. A
partial least square method on UV spectra was used to determine simultaneously the concentrations of the two
drugs at the egress of the terminal extension line. The drug mass flow rate (expressed as mg/h) was calculated as
the product of drug concentration versus total flow rate. Observed/theoretical mass flow rate ratios for each drug
(%) were determined per infusion condition.
Results: Even in the absence of visible particles, precipitation of furosemide led to a drug loss estimated at
between 10 % and 15 %. Furosemide is more impacted by interaction because the pH of the mixture is acid and
this form is poorly soluble in an aqueous solution.
Conclusions: Physical incompatibility between furosemide and midazolam leads to a significant reduction in drug
delivered to the patient and may result in treatment failure.
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Incompatibilities between drug solutions can jeopardize
the safety and effectiveness of intravenous drug therap-
ies, especially in the field of anesthesia and intensive care
therapy [1-3]. In fact, patients in intensive care units re-
ceive many drugs simultaneously but through limited
venous accesses. Several intravenous therapies have to
be administered through the same catheter, thus increas-
ing the risk of physicochemical incompatibility.* Correspondence: bertrand.decaudin@univ-lille2.fr
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in any medium, provided the original work is pPhysical incompatibilities result in visible (precipitate,
color change, gas production) and invisible (subvisible
particles, variations in pH) reactions. Chemical incom-
patibilities can lead to a decrease in drug delivery, drug
degradation, and/or production of toxic products. Physi-
cochemical incompatibilities have been reported in a series
of observational studies in intensive care units [4-7]. The
use of separate venous access sites can prevent contact be-
tween incompatible drugs, but all too often there are fewer
venous accesses than the number of drugs infused. Filters
also can be placed on the infusion line to prevent drug
particles from being administered to the patient. However,
they will not be able to prevent a drop in drug mass flow
rates resulting from incompatibility.
The purpose of this work was to assess and to quantify
the impact of physical incompatibility on the mass flowan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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using a single-lumen catheter, through an in vitro study.Methods
We have chosen to study furosemide-midazolam incom-
patibility, because these drugs are widely used in
anesthesia and intensive care units. This incompatibility
is due to an acid–base reaction. In an equivolume (1:1)
mixture, the formation of a visible milky-white precipi-
tate is immediate [8]. Because furosemide-midazolam in-
compatibility is pH-dependent, the impact of furosemide
concentration is predictable. Furosemide in 10 mg/mL
of saline is an alkaline solution (pH = 8.77). Mixing a
furosemide solution with an acidic solution (i.e., 5 mg/
mL midazolam, pH = 3.47) decreases the pH of the mix-
ture sufficiently to cause furosemide precipitation [9].
Furosemide and midazolam concentrations were simul-
taneously determined in the solution by UV spectropho-
tometry coupled with partial least square (PLS)
regression [10].
Furosemide (10 mg/mL Furosemide, Renaudin, France),
midazolam (5 mg/mL Midazolam, Mylan, France), and
saline (500 mL FreeflexW, Fresenius Kabi, France) were
simultaneously infused using syringe pumps connected
to a three-lumen infusion device (VSET + M, Doran
International, France) consisting of a central tube with
an antireflux valve for saline and two flexible low dead
volume tubes reserved for the furosemide and midazo-
lam infusions (Figure 1). An extension line (diameter =
1 mm, length = 25 cm) simulating the central venous
catheter was added at the distal end of the infusion set.
A 1.2-μm porosity filter (Lipipor TNA, Pall, France) was
added or not at the end of the infusion line. Three
50-mL syringes were prepared for each experiment:
one filled with furosemide diluted in saline at 10 or
2.5 mg/mL, one filled with midazolam diluted in saline
at 1 mg/mL, and one with saline only. The final drug
concentration was checked using a spectrophotometric
method before infusion.
Using unpublished results, we defined two infusion
conditions leading or not to visible particle formation.
The choice of drug concentrations was in accordanceFigure 1 Three-lumen infusion device (VSET + M) with the
central lumen reserved for carrier fluid and the two flexible low
dead volume tubes reserved for furosemide and midazolam
infusions.with clinical practice and infusion sets were used with
no filter:
1) 10 mg/mL of furosemide at 2 mL/h infusion rate,
1 mg/mL of midazolam at 2 mL/h, and saline at
100 mL/h (condition leading to visible particle
formation).
2) 2.5 mg/mL of furosemide at 8 mL/h infusion rate,
1 mg/mL of midazolam at 2 mL/h, and saline at
50 mL/h (condition not leading to visible particle
formation).
The infusion was first subjected to visual inspection,
and then, in the absence of visible particles, a 25-mL
sample was collected at the egress of the extension line.
Particle counts were taken using a particle counter
(APSS-2000, PMT, France). Tests were performed under
the conditions described in Chapter 2.9.19 of the 7.5th
European Pharmacopeia [11]. The infusion condition
complied with the subvisible particle count test for a
high volume as long as the average number of particles
present in the sample tested did not exceed 25 per mL
for particle sizes ≥10 μm and 3 per mL for particle sizes
≥25 μm. Each infusion condition was subjected to the
visual inspection test three times. Three particle counts
per sample were performed for the condition not leading
to visible particle formation. All tests were performed at
room temperature between 18 °C and 22 °C.
Our study was divided into two parts. In the first, we
revalidated the two infusion conditions, following the
same methods. In the second, for each infusion condi-
tion tested, we determined the mass flow rates of fur-
osemide and midazolam on the infusion line with and
without filter. Five trials were made per infusion condi-
tion tested. Drug concentrations in the mixture at the
egress of the infusion line were determined using UV
spectrophotometry (model UV-2450, Shimadzu, France)
and partial least square (PLS) analysis. All information
from the spectrophotometer was collected with UV
Probe 2.21 software (Shimadzu, France). A partial least
square (PLS) method on UV spectra was used to deter-
mine simultaneously the concentrations of the two drugs
at the egress of the terminal extension line.
PLS regression is a simple and powerful multivariate
method based on factor analysis and is used for building
regression models based on latent variable decompos-
ition relating a block of independent variables, x (spec-
tra), to a block of dependent ones, y (concentrations).
PLS regression was obtained using the PLS module of
XLSTAT software version 2011.2.01 (Addinsoft, France).
The 220–320 nm spectral zone was used to obtain the
best model. The recovery percentage was in the 100.14–
101.25 % range. Detection limits (LOD = 3.3 x standard
deviation/gradient) of drugs in mixtures were 0.19 μg/mL
Table 1 Determination of drug mass flow rates for the


































































































*P = 0.005 (observed vs. theoretical value).
**P = 0.001 (observed vs. theoretical value).
***P < 0.001 (observed vs. theoretical value).
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quantification limits (LOQ = 10 x standard deviation/
gradient) were 0.57 μg/mL for furosemide and 1.10 μg/
mL for midazolam. Selectivity, calculated from the net
analyte signal, was equal to 0.18 and 0.2 for furosemide
and midazolam respectively. Because these exceeded the
spectrophotometer’s linear range, they were diluted in
saline. The drug mass flow rate (expressed as mg/h) was
calculated as the product of drug concentration against
total flow rate. Observed/theoretical mass flow rate
ratios for each drug (%) also were determined per infu-
sion condition. Measurements of pH were performed on
drug solutions at the egress of infusion device using a
pH meter (PHM201 MeterLab, Radiometer Analytical,
Villeurbanne, France).
The Student’s t test was used to compare observed
and theoretical drug mass flow rates and filtered and
nonfiltered data after performing the Shapiro-Wilk test
to check that the data observed was normally distribu-
ted. Results are expressed as mean values ± standard
deviations (± SD) of mass flow rates. The level of signifi-
cance was established at 0.05.
Results and Discussion
The results are presented in Table 1. For the infusion
condition that did not lead to the formation of visible
particles, the number of subvisible particles was in ac-
cordance with the threshold defined by the European
Pharmacopeia (18.6 and 0.4/mL for particles ≥ 10 μm
and ≥ 25 μm, respectively).
Results are expressed as mean values ± standard devia-
tions (SD) of mass flow rates and pH values. Observed/
theoretical mass flow rate (%) ratios were also deter-
mined for each drug per infusion condition.
Furthermore, for both drugs, the observed mass flow
rates varied little with or without filter on the infusion
set. For midazolam, observed mass flow rates were simi-
lar to theoretical values (ratios close to 100 %) whatever
the infusion conditions. For furosemide, however,
observed mass flow rates were significantly different
from theoretical values whatever the infusion conditions.
The lowest furosemide mass flow rate value was found
for the infusion condition leading to visible particles
where a 14 % loss was observed compared with theoret-
ical values (ratios equal to 86 %). Even in the absence of
visible particles, a furosemide loss of approximately 7–
10 % compared with theoretical values was noted (ratios
equal to 90 % and 93 % with filter and without filter, re-
spectively). For both infusion conditions, the addition of
a filter to the infusion set had no effect on the observed
mass flow rates of the two drugs.
This study highlights the reduction in drug mass flow
rates when physical incompatibility occurs between two
drugs. Preventing incompatibility is important if injectabledrugs are to be safely administered. In “high-risk” cases
where drug incompatibility is very probable, the use of a
filter protects the patient against particle emboli. Never-
theless, the filter does not prevent drug loss in the case of
precipitation. In this study, furosemide precipitation
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ticles led to a drug loss to the patient estimated at between
10 % and 15 %. This was not caused by interaction with
the filter, because similar results were obtained with or
without filter. Furosemide was more impacted by the
interaction of the two drugs as the pH of the mixture is
acid (Table 1), and furosemide in its acidic form is poorly
soluble in an aqueous solution [12]. For a substance to be
soluble in water, it must be in its ionized form, which is
not the case here for furosemide [9]. The impact of mixing
conditions (concentration and flow rates) on particle for-
mation also must be taken into consideration as the pH
levels of mixed solutions were similar at the end of the ex-
tension line. This reduction in drug delivery should not
have any clinical impact in the case of furosemide. Never-
theless, this result raises the issue for other mixtures of
acid (amiodarone, ciprofloxacin, dobutamine, midazolam,
norepinephrine) and alkaline (acyclovir, furosemide,
phenytoin) drug solutions that may lead to physical
incompatibilities. The major consequence for the patient
could be therapeutic failure, especially in the case of drugs
with a narrow therapeutic index.
It should be noted that there are several limitations to
this study. Our assessment was limited to a two-drug
combination inducing pH-dependent incompatibility.
The results may vary with other drug combinations. Our
results should be confirmed by testing other combina-
tions of incompatible drugs and more than two drugs
among those commonly used in intensive care and
anesthesia.
Conclusions
Physical incompatibility between two drugs may lead to
a significant reduction in drug amount delivered to the
patient even in the absence of precipitate. Physicians,
nurses, and pharmacists must be sensitive to the perfu-
sion conditions of simultaneously infused drugs. The ab-
sence of precipitate does not necessarily mean the
absence of reaction between drugs.
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